Therapy News and Research

RSS

Phase III studies show tiotropium delivered via Respimat inhaler proves effective in asthma patients

Boehringer Ingelheim today announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities.

3 Mar 2014

Randomized trial of bevacizumab for glioblastoma shows disappointing results

"The results of this study are counter to most expectations," said Dr. Brachman, Director of Radiation Oncology at Barrow and St. Joseph's. "Bevacizumab had been shown in earlier studies to be an effective drug in the treatment of patients with recurrent disease. But, on newly diagnosed patients, it did not, in fact, prolong survival."

3 Mar 2014

Researchers identify mutations in gene that can reduce risk of developing type 2 diabetes

An international team led by researchers at the Broad Institute and Massachusetts General Hospital (MGH) has identified mutations in a gene that can reduce the risk of developing type 2 diabetes, even in people who have risk factors such as obesity and old age.

3 Mar 2014

Asthma drug accelerates desensitization in patients with food allergies to several foods

An asthma drug accelerates the process of desensitizing patients with food allergies to several foods at the same time, a new study by researchers at the Stanford University School of Medicine and Lucile Packard Children's Hospital Stanford shows.

3 Mar 2014

Xeltis completes enrollment for study of spontaneous tissue growth technology

Xeltis, a privately held medical device company dedicated to transforming standards of care in heart valve replacement and vascular surgery, has announced that it has finished enrollment in a five-patient feasibility study of implantable products intended to enable for the first time the spontaneous growth of natural, healthy heart valves and vessels. With its proprietary technology, the company has pioneered an entirely new therapeutic category called Endogenous Tissue Growth, or ETG, in which surgeons use unique implants designed to allow the body to repair itself by growing natural, healthy tissue.

28 Feb 2014

Abingworth announces final closing of £225M ($375M) fund

Abingworth, the international investment group dedicated to life sciences and healthcare, today announced the final closing of its £225m ($375m) fund, Abingworth Bioventures VI (ABV VI). ABV VI, Abingworth's 10th life sciences fund, exceeded its target of £200 million and invests in life sciences and healthcare both in Europe and the US.

28 Feb 2014

Auxilium Pharmaceuticals’ net revenues increase $125.9M to 56%

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced financial results for the fourth quarter and full year ending December 31, 2013. The Company also highlighted select commercial, regulatory and clinical development progress and future goals and provided financial guidance for 2014.

28 Feb 2014

ACCRU opens phase III clinical trial of eribulin compared to paclitaxel for metastatic breast cancer

Academic and Community Cancer Research United (ACCRU) today announced the opening of a two-arm, randomized phase III, FDA registration trial of eribulin compared to standard weekly paclitaxel as first- or second-line chemotherapy for individuals with human epidermal growth factor receptor 2 (HER2) negative, locally recurrent, unresectable or metastatic breast cancer.

28 Feb 2014

Academy of Nutrition and Dietetics celebrates contributions of registered dietitian nutritionists

March is National Nutrition Month®, when the Academy of Nutrition and Dietetics reminds everyone to return to the basics of healthful eating. It is also the time of year when the Academy celebrates the contributions and expertise of registered dietitian nutritionists as the food and nutrition experts.

28 Feb 2014

Cedars-Sinai neurosurgeon successfully performs CSF repair surgery on patient

When Elizabeth "Beth" Johnson stood up from working at her computer Oct. 28, she noticed "a kind of funny feeling" in the back of her neck. By Nov. 2, the sensation had become an excruciating headache that came on whenever she tried to stand or sit upright.

28 Feb 2014

Celsion reports positive interim data from Phase 2 DIGNITY Trial of ThermoDox in RCWBC

Celsion Corporation announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox in Recurrent Chest Wall Breast Cancer.

28 Feb 2014

Vétoquinol acquires Bioniche's Animal Health business

Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced their signing of a share purchase agreement under which Vétoquinol has agreed to purchase Bioniche's Animal Health business for the cash purchase price of CAD$61 million.

28 Feb 2014

New procedure offers benefits for patients with severe asthma

Like millions of people, Jeannine Childs suffers from asthma. But unlike most, her asthma was debilitating. For years she struggled with wheezing, shortness of breath and fits of coughing so severe that they often landed her in the hospital. Nothing was really working – not lifestyle changes, not medications.

28 Feb 2014

Vaccine targeting tumors could initiate immune response to fight cancer

Cincinnati Cancer Center (CCC) and UC Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune system, could initiate the immune response to fight cancer.

28 Feb 2014

Chemo and radiation can kill more cancer cells and spare healthy ones, suggests Rutgers research

What if there were a way to make chemotherapy and radiation more effective as cancer treatments than they are today, while also getting rid of debilitating side effects that patients dread? A new study led by Alexey Ryazanov, a professor of pharmacology at Rutgers Robert Wood Johnson Medical School and member of the Rutgers Cancer Institute of New Jersey, suggests the day that happens could be getting closer.

27 Feb 2014

Ophthotech reports net loss of $20.4 million for fourth quarter 2013

Ophthotech Corporation today announced financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on the Company's business and product development programs.

27 Feb 2014

Researchers launch new programme to remotely monitor patients undergoing chemotherapy

Researchers from the University of Surrey have today launched a new programme of research called eSMART (Electronic Symptom Management using ASyMS Remote Technology), that uses mobile phone technology to remotely monitor patients who are undergoing chemotherapy to treat breast, bowel and blood cancers.

27 Feb 2014

NAFC designates Beth Israel Deaconess Medical Center as Center of Excellence

The National Association For Continence has designated Beth Israel Deaconess Medical Center as a Center of Excellence: Continence Care. Anurag K. Das, MD; Roger Lefevre, MD; Janet Li, MD; and Deborah A. Nagle, MD are the principle physicians for this COE.

27 Feb 2014

Simple change in hospital laboratory reports may improve antibiotic prescribing practices

A simple change in how the hospital laboratory reports test results may help improve antibiotic prescribing practices and patient safety, according to a pilot, proof-of-concept study published in Clinical Infectious Diseases and now available online.

27 Feb 2014

Tissue repair drug can improve healing rates in people with diabetic foot ulcer

Patients were twice as likely to have a diabetic foot ulcer heal within eight weeks when they were treated with a tissue repair drug versus a placebo, according to new research accepted for publication in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

27 Feb 2014

Therapy News and Research

Phase III studies show tiotropium delivered via Respimat inhaler proves effective in asthma patients

Randomized trial of bevacizumab for glioblastoma shows disappointing results

Researchers identify mutations in gene that can reduce risk of developing type 2 diabetes

Asthma drug accelerates desensitization in patients with food allergies to several foods

Xeltis completes enrollment for study of spontaneous tissue growth technology

Abingworth announces final closing of £225M ($375M) fund

Auxilium Pharmaceuticals’ net revenues increase $125.9M to 56%

ACCRU opens phase III clinical trial of eribulin compared to paclitaxel for metastatic breast cancer

Academy of Nutrition and Dietetics celebrates contributions of registered dietitian nutritionists

Cedars-Sinai neurosurgeon successfully performs CSF repair surgery on patient

Celsion reports positive interim data from Phase 2 DIGNITY Trial of ThermoDox in RCWBC

Vétoquinol acquires Bioniche's Animal Health business

New procedure offers benefits for patients with severe asthma

Vaccine targeting tumors could initiate immune response to fight cancer

Chemo and radiation can kill more cancer cells and spare healthy ones, suggests Rutgers research

Ophthotech reports net loss of $20.4 million for fourth quarter 2013

Researchers launch new programme to remotely monitor patients undergoing chemotherapy

NAFC designates Beth Israel Deaconess Medical Center as Center of Excellence

Simple change in hospital laboratory reports may improve antibiotic prescribing practices

Tissue repair drug can improve healing rates in people with diabetic foot ulcer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News